PD-1 Tumor Suppressor Signaling in T Cell Lymphomas

T cell lymphomas are aggressive cancers characterized by oncogenic mutations in TCR signaling pathways. PD-1 is a central tumor suppressor in T cell lymphoma that is frequently inactivated in human T-NHL. PD-1 activity within malignant human and mouse T cells can negatively regulate the PI3K/AKT and PKCθ/NF-κB tumor survival pathways. PD-1 targeting checkpoint inhibitors can also accelerate T cell lymphomas under still-undefined conditions. The inhibitory receptor PD-1 is critical to balancing antigen-induced T cell activation; its inhibition is currently being explored to enhance antitumor T cell immunity with certain successful outcomes. However, PD-1 has also emerged as a central tumor suppressor in T cell lymphomas, where the tumor cell originates from a T cell itself. These aggressive cancers are frequently characterized by oncogenic mutations in T cell receptor (TCR) signaling pathways. PD-1 activity within malignant T cells can negatively regulate the PI3K/AKT and PKCθ/NF-κB tumor survival pathways and PD-1 is frequently inactivated in this human malignancy. This review summarizes current insights into oncogenic T cell signaling, discusses tumor-suppressive functions and mechanisms of PD-1 in T cell lymphomagenesis, and addresses potential unwanted effects caused by PD-1 checkpoint inhibition. The inhibitory receptor PD-1 is critical to balancing antigen-induced T cell activation; its inhibition is currently being explored to enhance antitumor T cell immunity with certain successful outcomes. However, PD-1 has also emerged as a central tumor suppressor in T cell lymphomas, where the tumor cell originates from a T cell itself. These aggressive cancers are frequently characterized by oncogenic mutations in T cell receptor (TCR) signaling pathways. PD-1 activity within malignant T cells can negatively regulate the PI3K/AKT and PKCθ/NF-κB tumor survival pathways and PD-1 is frequently inactivated in this human malignancy. This review summarizes current insights into oncogenic T cell signaling, discusses tumor-suppressive functions and mechanisms of PD-1 in T cell lymphomagenesis, and addresses potential unwanted effects caused by PD-1 checkpoint inhibition. neoplasm of mature T cells etiologically linked to HTLV-1. Disease manifestations are subcategorized depending on their clinical course: acute, chronic, smoldering, lymphoma. distinguished from other lymphomas by their anaplastic cytology and constant surface expression of CD30. characterized by generalized lymphadenopathy, high fever, skin rash, and autoimmune-like manifestations. AITL tumor cells share characteristics with TFH cells. antigen-experienced T cell that expresses CD45RO, CCR7, and CD62L. represent a heterogeneous group of lymphomas characterized by abnormal accumulation of malignant T cells in the skin. T cell exhaustion is a state of T cell dysfunction that develops during cancer and chronic infections. It is defined by poor effector functions, persistent surface expression of inhibitory receptors and a distinct transcriptional profile. decrease in copy number of a genomic DNA segment, limited to a small fraction of a chromosome. one of several forms of peripheral T cell lymphomas recognized in the past decade; it is thought to originate from follicular helper T cells. genetic mutation caused by insertion or deletion of a number of nucleotides in a DNA sequence that is not divisible by three. interface between an antigen-presenting cell or target cell and a lymphocyte such as a T cell, B cell, or natural killer cell. organized compositions of glycosphingolipids and protein receptors in glycolipoprotein lipid microdomains in the plasma membrane. most common form of cutaneous T cell lymphoma. Symptoms include rash, tumors, skin lesions, and itchy skin. T-NHL subcategory that includes angioimmunoblastic T cell lymphoma; nodal peripheral T cell lymphoma with T follicular helper phenotype; peripheral T cell lymphoma, not otherwise specified; and follicular T cell lymphoma. aggressive form of cutaneous T cell lymphoma. In SS, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. a variation in a single nucleotide without any limitations of frequency. distinct subset of antigen-experienced CD4+ T cells that regulate the development of antigen-specific B cell immunity. aggressive neoplasm of precursor T cells that occurs mostly in young adults. genomic technique for sequencing all protein-coding regions in the genome of an organism. the process of determining the complete genomic DNA sequence of an organism.